Prodromal Inclusion/Exclusion Criteria O of 11 completed **Assessment Date** 11/09/2020 **Inclusion Criteria** 1. Enrolled in PPMI 2.0 Remote and based on remote assessments, including hyposmia, are eligible for PPMI 2.0 Clinical. No Yes 2. Male or female age 60 years or older (except age 30 years or older for SNCA, or rare genetic mutations (such as Parkin or Pink1) participants). No Yes 3. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 halflives before DaTscan imaging. No Yes 4. Confirmation that participant is eligible based on Screening DaTscan imaging. No Yes 5. Able to provide informed consent. No Yes

6. Women may not be pregnant, lactating or planning pregnancy during the study.		
○ No	Yes	
Includes a negative pregnancy test on day of Screening DaTscan imaging test prior to injection of DaTscan.		
Exclusion Criteria		
1. Clinical diagnosis of PD, other parkinsonism, or dementia.		
○ No	Yes	
2. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.		
○ No	Yes	
3. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture.		
○ No	Yes	
4. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.		
○ No	Yes	
5. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.		
○ No	Yes	